Martin Reck

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial.

The phase 2 MDT-BRIDGE study is investigating perioperative durvalumab plus neoadjuvant chemotherapy (AEGEAN regimen) in resectable and borderline resectable non-small-cell lung cancer and chemoradiotherapy (CRT) followed by consolidation durvalumab (PACIFIC regimen) in patients who become unresectable after neoadjuvan...

Lung cancer after allogeneic hematopoietic stem cell transplantation.

INTRODUCTION Long-term outcomes of allogeneic hematopoietic cell transplantation (HCT) are improving, increasing the relevance of secondary malignancies, including lung cancer. The clinical utility of immune checkpoint inhibitors (ICIs) in this setting remains unclear and concerns regarding graft-versus-host disease (G...

Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC

In a large international real-world study of non-small cell lung cancer, a multimodal explainable AI model outperformed established biomarkers for immunotherapy outcome prediction and improved physician decision-making.